TXNDC5 and ovarian cancer: Auranofin (AF) as an anti-inflammatory and anti-cancer drug, upregulated TXNDC5 expression and protein oxidation in ovarian cancer cells where TXNDC5 upregulation compensated for the deficiency of PDI activity in the ER [30,56].